Psyence BioMed unit signs term sheet for exclusive US ibogaine license, supply deal with PsyLabs

Bitget2026/09/28 11:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Psyence Biomedical’s Texas unit TIRC signed a binding term sheet for an exclusive U.S. license to PsyLabs’ pharmaceutical-grade ibogaine.
Definitive agreement targeted by Nov. 30, 2026; term sheet lapses if no deal is signed by that date.
Arrangement includes exclusive U.S. supply from PsyLabs, with TIRC as exclusive U.S. wholesaler and distributor.
Economics include up to about USD 1.3 million in development and regulatory milestones for the first drug candidate.
Also includes an annual exclusivity fee starting after first FDA approval, plus low single-digit royalties on net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280700PRIMZONEFULLFEED9834722) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Psyence BioMed unit signs term sheet for exclusive US ibogaine license, supply deal with PsyLabs

You may also like

Crypto prices